What is TLPH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TLPH?

P/E (TTM) is n/a and 52-week range is $0.69 to $1.57 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TLPH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TLPH?

The company profile lists revenue (TTM) near $952M, net income (TTM) near -$485M, EPS (TTM) near -$0.26 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Talphera Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Mateo, California, US, 51.9M shares outstanding, ISIN US00444T2096 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Talphera Inc

$TLPH

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 12 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Employees

Website

talphera.com

IPO

2011-02-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US00444T2096

Headquarters

San Mateo, California, US

Shares outstanding

51.9M

NAICS sector

Manufacturing

Institutional ownership

39.49%

Browse other companiesFree AI scores and summaries for more stocks